PRODUCT TYPES – Page 12

Aseptic manipulation deviation during tech transfer: inspection-ready investigation package

Identifying symptoms or signals of a deviation during aseptic manipulation is crucial for timely mitigation. Common indicators may include:Click to read the full article.

Finished product serialization data mismatch after method transfer to a new QC lab: updates to master batch record and in-process controls to prevent recurrence

Upon transferring serialization methods to a new QC lab, several observable symptoms may indicate a problem:Click to read the full article.

Aseptic manipulation deviation during stability testing: regulatory risk assessment and CAPA

The first step in addressing any potential aseptic manipulation deviation is recognizing symptoms or signals that emerge on the manufacturing floor or within laboratory environments. Symptoms may manifest as unusual…

Finished product transport excursion stability impact during deviation triage meeting: risk assessment for patient impact and field alert / recall triggers

Identifying the key symptoms that indicate a finished product transport excursion is the first step in any investigation. Common symptoms may include:Click to read the full article.

Chain of identity breach during stability testing: regulatory risk assessment and CAPA

The initial signs of a chain of identity breach can manifest in several ways. Understanding these symptoms is critical for initiating timely investigations. Common signals include:Click to read the full…

Finished product particulate matter OOS during line clearance and changeover: updates to master batch record and in-process controls to prevent recurrence

Symptoms indicating a potential OOS for finished product particulate matter often arise during routine observations or laboratory testing. Key signals to monitor include:Click to read the full article.

Cross-contamination risk during stability pull: FDA/EMA investigation expectations

Identifying symptoms of cross-contamination during stability pulls can be crucial in preventing wider issues. Indicators can be both operational and analytical:Click to read the full article.

Finished product particulate matter OOS during stability pull at accelerated conditions: stability strategy adjustments and packaging risk mitigation steps

The first step in addressing an OOS related to particulate matter is recognizing the symptoms or signals that indicate a potential issue. Common observations include:Click to read the full article.

Cross-contamination risk during inspection prep: risk assessment for patient safety

Assessing Cross-Contamination Risks During Inspection Preparation in Pharma Manufacturing Cross-contamination risk during inspection preparation can pose significant challenges to pharmaceutical manufacturing, especially in sectors like oncology where patient safety is…

Finished product appearance defect complaints during line clearance and changeover: how to defend specification setting and outlier handling during inspection

Complaints about finished product appearance defects often serve as early warning signals indicating deeper issues in the manufacturing process. Symptoms may include:Click to read the full article.

Cross-contamination risk during shared facility campaign: risk assessment for patient safety

Identifying symptoms or signals of potential cross-contamination is the first step in mitigating risks. These signals can manifest as deviations from expected outcomes, which include:Click to read the full article.

Finished product transport excursion stability impact during EMA/MHRA inspection preparation: updates to master batch record and in-process controls to prevent recurrence

When a transport excursion occurs, certain symptoms or signals may be observed both on the production floor and within the laboratory settings. These indicators are critical in the initial identification…